STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersThe number of measles cases in the U.S. has surpassed the record-breaking tally for all of 2025, with five more months of 2026 still to come.
By Chella·1h agoWhy it mattersIn a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the drugs
By Chella·4h ago
Why it mattersThe Trump administration released its blueprint for U.S. science, calling for shifting hundreds of billions of research dollars from universities to industry.
By Chella·9h ago
Why it mattersMirroring the bipartisan bill introduced in the House, the measure would require a study from the GAO on the state of men’s health in the U.S. to be presented within…
By Chella·1d ago